Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epiitalis is a proprietary, globally patented plant seed oil extract derived from *Biota orientalis*, developed by Interpath, and formulated as a dietary supplement for joint health in both humans and animals. It is characterized by unique fatty acids and is designed to reduce inflammation, enhance cartilage health, and support normal joint function. Epiitalis has been studied in multiple species—including humans, dogs, horses, and cats—and has demonstrated significant efficacy in reducing pain, improving joint function, and improving quality of life, particularly in osteoarthritis. Clinical studies show approximately 50% pain reduction in human knee osteoarthritis patients versus placebo, with similar improvements in function and quality of life. The precise molecular mechanism is under continued investigation, but evidence supports an anti-inflammatory effect and possible disease-modifying activity in joint pathology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on epiitalis.